1192322-79-4

Upstream product

• 1192322-55-6 3-{4-[(3-methoxycarbonyl-phenyl-carbamoyl)-methoxy]-phenyl}-adamantane-1-carboxylic acid 
• 107890-32-4 1-(4-trifluoromethylbenzyl)piperazine 
• 4518-10-9 Methyl 3-aminobenzoate 
• 1192322-53-4 3-(4-[(3-methoxycarbonylphenylcarbamoyl)methoxy]phenyl)adamantane-1-carboxylic acid benzylester 

Relevant academic research and scientific papers

Design, synthesis and structure-activity relationship studies of novel 4 (1-adamantyl) phenyl analogues as hif-1α inhibitors

Hypoxia inducible factor-1 (HIF-1) is a key mediator during cancer cells to adapt tumor hypoxic condition. In this study, a series of adamantane-based compounds were synthesized and evaluated as potential inhibitors of HIF-1α. Examination of their structu

A novel class of highly potent multidrug resistance reversal agents: Disubstituted adamantyl derivatives

Novel disubstituted adamantyl derivatives were synthesized and evaluated in a P-glycoprotein dependent multidrug resistance cancer cell line. The hit to lead optimization provided potent MDR reversal agents. Some potent adamantyl derivatives were more than 10-fold more potent than verapamil without considerable intrinsic cytotoxicity. The 3-trifluorophenyl derivative 14f did not affect the metabolism of CYP450 3A4, whereas most of MDR revertants had a weak inhibitory effect.